Helix Acquisition CORP Ii Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Citadel entities and Kenneth Griffin report a 3.2% beneficial ownership in BridgeBio Oncology Therapeutics, Inc. Class A ordinary shares.
Adage Capital Management and its principals have filed an amended Schedule 13G, reporting a 1.88% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc.
BC Global Opportunities IX LP and affiliated entities have disclosed a 5.51% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. common stock.
Deerfield Management and affiliated funds have disclosed a passive 6.17% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. common stock.
Millennium Management and related entities have disclosed beneficial ownership of up to 4.7% of Helix Acquisition Corp. II's Class A Ordinary Shares.
Sculptor Capital LP and its affiliates have reported a beneficial ownership of 5.12% in Helix Acquisition Corp II's Class A Ordinary Shares, totaling 967,460 shares.
SCHEDULE 13G/A: BlackRock Divests Entire Reportable Stake in Helix Acquisition Corp. II Class A Stock
BlackRock, Inc. has filed an amended Schedule 13G indicating it no longer holds a reportable beneficial ownership stake in Helix Acquisition Corp. II's Class A Stock, now owning 0%.
BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting a 7.9% beneficial ownership in Helix Acquisition II Corp.'s Class A Common Stock as of March 31, 2025.